MedPath

Benefit of Adding Chemotherapy for Advance Nasopharyngeal Carcinoma (T1-4N2-3M0)

Not Applicable
Conditions
Nasopharyngeal Neoplasms
Carcinoma, Squamous Cell
Registration Number
NCT00563927
Lead Sponsor
Hospital Authority, Hong Kong
Brief Summary

To test the therapeutic ratio of additional chemotheray on advanced nasopharyngeal carcinoma.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
340
Inclusion Criteria
  • Undifferentiated or non-keratinizing carcinoma
  • Tumor staged as N2-3
  • No evidence of distant metastasis M0
  • Performance status:0-2
  • Marrow: WBC >= 4 and platelet >= 100
  • Renal: creatinine clearance >= 60
  • Informed consent
Read More
Exclusion Criteria
  • WHO type I squamous cell carcinoma or adenocarcinoma
  • Age >= 70
  • Palliative intent or tumor extent mandating AP opposing facio-cervical fields
  • Prior malignancy except adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease-free for 5 years
  • Previous radiotherapy (except non-melanomatous skin cancers outside the intended RT treatment volume
  • Previous chemotherapy
  • Patient is pregnant or lactating
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Failure free survival rate5 year
Secondary Outcome Measures
NameTimeMethod
Disease-specific survival rate5-year
Overall survival rate5-year
Complication-free rates5-year

Trial Locations

Locations (4)

Pamela Youde Nethersole Eastern Hospital

🇨🇳

Hong Kong, China

Tuen Mun Hospital

🇨🇳

Hong Kong, China

Queen Elizabeth Hospital

🇨🇳

Hong Kong, China

Queen Mary Hospital

🇨🇳

Hong Kong, China

© Copyright 2025. All Rights Reserved by MedPath